ATORX BTU Stock Overview
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Alligator Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.06 |
| 52 Week High | kr1.50 |
| 52 Week Low | kr1.01 |
| Beta | 1.34 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATORX BTU | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.4% | 2.8% | 1.4% |
| 1Y | n/a | -3.2% | 8.6% |
Return vs Industry: Insufficient data to determine how ATORX BTU performed against the Swedish Biotechs industry.
Return vs Market: Insufficient data to determine how ATORX BTU performed against the Swedish Market.
Price Volatility
| ATORX BTU volatility | |
|---|---|
| ATORX BTU Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.4% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: ATORX BTU has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ATORX BTU's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 58 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG
Alligator Bioscience AB (publ) Fundamentals Summary
| ATORX BTU fundamental statistics | |
|---|---|
| Market cap | kr753.49m |
| Earnings (TTM) | -kr248.59m |
| Revenue (TTM) | kr59.25m |
12.7x
P/S Ratio-3.0x
P/E RatioIs ATORX BTU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATORX BTU income statement (TTM) | |
|---|---|
| Revenue | kr59.25m |
| Cost of Revenue | kr218.79m |
| Gross Profit | -kr159.54m |
| Other Expenses | kr89.05m |
| Earnings | -kr248.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -269.26% |
| Net Profit Margin | -419.55% |
| Debt/Equity Ratio | 0% |
How did ATORX BTU perform over the long term?
See historical performance and comparison